Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse

Neuroscience

Volumn 122, Issue 4, 2003, Pages 1049-1057

  Naver, B ^a   Stub, C ^b   Moller M ^a   Fenger, K ^a   Hansen, A K ^b   Hasholt, L ^a   Sorensen S A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Behavior; Cannabinoid receptor 1; Developmental instability; Fluctuating asymmetry; Neuronal inclusions

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID 1 RECEPTOR; CYCLIC AMP; DOPAMINE; MESSENGER RNA; METENKEPHALIN; PHOSPHOPROTEIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BODY WEIGHT; BRAIN NERVE CELL; CELL INCLUSION; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DEVELOPMENTAL STABILITY; EXON; EXPERIMENTAL MODEL; FEMALE; FORELIMB; HEMIZYGOSITY; HINDLIMB; HUNTINGTON CHOREA; LIMB MOVEMENT; MAZE TEST; MOTOR ACTIVITY; MOTOR COORDINATION; MOUSE; NONHUMAN; OPEN FIELD BEHAVIOR; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR DOWN REGULATION; TRANSGENIC MOUSE; WILD TYPE;

EID: 0345304253     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2003.08.053     Document Type: Article

References (36)

1. Carter R.J., Lione L.A., Humby T., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci. 19:1999;3248-3257.
2. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA. 95:1998;6480-6485.
3. Chicurel, M, Hurlbert, MS, Schweitzer, E, Yamamoto, A (2000) Expression of Huntington's disease mutation in mice. 1. American HD Organization. http://www.hdfoundation.org/PDF/hdmicetable.pdf.
4. Clifford J.J., Drago J., Natoli A.L., Wong J.Y., Kinsella A., Waddington J.L., Vaddadi K.S. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience. 109:2002;81-88.
5. Denovan-Wright E.M., Robertson H.A. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice. Neuroscience. 98:2000;705-713.
6. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 277:1997;1990-1993.
7. DiFiglia M., Sapp E., Chase K.O., Schwarz C., Meloni A., Young C., Martin E.J., Vonsattel J.P., Carraway R., Reeves S., Boyce F.M., Aronin N. Huntingtin is a cytoplasmatic protein associated with vesicles in human and rat brain neurons. Neuron. 14:1995;1075-1081.
8. File S.E., Mahal A., Mangiarini L., Bates G.P. Striking changes in anxiety in Huntington's disease transgenic mice. Brain Res. 805:1998;234-240.
9. Glass M., Dragunow M., Faull R.L. The pattern of neurodegeneration in Huntington's disease a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease . Neuroscience. 97:2000;505-519.
10. Glass M., Faull R.L., Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Neuroscience. 56:1993;523-527.
11. Hansson O., Guatteo E., Mercuri N.B., Bernardi G., Li X.J., Castilho R.F., Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci. 14:2001;1492-1504.
12. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 23:1999;181-192.
13. Katznelson M.B., Bejerano M., Yakovenko K., Kobyliansky E. Relationship between genetic anomalies of different levels and deviations in dermatoglyphic traits. Part 4 Dermatoglyphic peculiarities of males and females with Down syndrome . Family Study Anthropol Anz. 57:1999;193-255.
14. Krohn T.C., Hansen A.K. The application of traditional behavioral and physiological methods for monitoring of the welfare impact of different flooring conditions in rodents. Scand J Lab Animal Sci. 29:2002;79-89.
15. Lastres-Becker I., Berrendero F., Lucas J.J., Martin-Aparicio E., Yamamoto A., Ramos J.A., Fernandez-Ruiz J.J. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB(1) receptors in the basal ganglia of a transgenic model of Huntington's disease. Brain Res. 929:2002;236-242.
16. Lastres-Becker I., Hansen H.H., Berrendero F., De Miguel R., Perez-Rosado A., Manzanares J., Ramos J.A., Fernandez-Ruiz J. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse. 44:2002;23-35.
17. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci. 19:1999;10428-10437.
18. Luesse H.G., Schiefer J., Spruenken A., Puls C., Block F., Kosinski C.M. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease behavioral testing and impact of diabetes mellitus . Behav Brain Res. 126:2001;185-195.
19. MacMillan J., Quarrell O. The neurobiology of Huntington's disease. Harper P.S. Huntington's disease. 1996;317-357 Saunders, London.
20. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87:1996;493-506.
21. Markow T.A., Wandler K. Fluctuating dermatoglyphic asymmetry and the genetics of liability to schizophrenia. Psychiatry Res. 19:1986;323-328.
22. Menalled L., Zanjani H., MacKenzie L., Koppel A., Carpenter E., Zeitlin S., Chesselet M.F. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease. Exp Neurol. 162:2000;328-342.
23. Nicklas W., Baneux P., Boot R., Decelle T., Deeny A.A., Fumanelli M., Illgen-Wilcke B. Recommendations for the health monitoring of rodent and rabbit colonies in breeding and experimental units. Lab Anim. 36:2002;20-42.
24. Norremolle A., Riess O., Epplen J.T., Fenger K., Hasholt L., Sorensen S.A. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet. 2:1993;1475-1476.
25. Nucifora F.C. Jr, Sasaki M., Peters M.F., Huang H., Cooper J.K., Yamada M., Takahashi H., Tsuji S., Troncoso J., Dawson V.L., Dawson T.M., Ross C.A. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 291:2001;2423-2428.
26. Reddy P.H., Williams M., Charles V., Garrett L., Pike-Buchanan L., Whetsell W.O. Jr, Miller G., Tagle D.A. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet. 20:1998;198-202.
27. Reisine T.D., Fields J.Z., Stern L.Z., Johnson P.C., Bird E.D., Yamamura H.I. Alterations in dopaminergic receptors in Huntington's disease. Life Sci. 21:1977;1123-1128.
28. Sanudo-Pena M.C., Tsou K., Walker J.M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci. 65:1999;703-713.
29. Schilling G., Becher M.W., Sharp A.H., Jinnah H.A., Duan K., Kotzuk J.A., Slunt H.H., Ratovitski T., Cooper J.K., Jenkins N.A., Copeland N.G., Price D.L., Ross C.A., Borchelt D.R. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet. 8:1999;397-407.
30. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D.R., Myers R.M. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet. 8:1999;763-774.
31. Stub C., Ritskes-Hoitinga M., Thon R., Hansen C.K., Hansen A.K. Fluctuating asymmetry in mice and rats evaluation of the method . Lab Anim. 36:2002;193-199.
32. Sun Z., Del Mar N., Meade C., Goldowitz D., Reiner A. Differential changes in striatal projection neurons in R6/2 transgenic mice for Huntington's disease. Neurobiol Dis. 11:2002;369-385.
33. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 72:1993;971-983.
34. van Dellen A., Welch J., Dixon R.M., Cordery P., York D., Styles P., Blakemore C., Hannan A.J. N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport. 11:2000;3751-3757.
35. Watase K., Weeber E.J., Xu B., Antalffy B., Yuva-Paylor L., Hashimoto K., Kano M., Atkinson R., Sun Y., Armstrong D.L., Sweatt J.D., Orr H.T., Paylor R., Zoghbi H.Y. A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron. 34:2002;905-919.
36. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell. 101:2000;57-66.